Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

308.30 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup Caution ↗

September 28, 2026

Via Chartmill

If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today ↗

September 02, 2026

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals...

Via Benzinga

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital ↗

August 26, 2026

Ligand Pharmaceuticals (NASDAQ:LGND) outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage...

Via MarketBeat

$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today ↗

August 21, 2026

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 10 years by 2.79% on an annualized basis producing an average annual return of 16.18%. Currently, Ligand Pharmaceuticals...

Via Benzinga

Ligand (LGND) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

XOMA acquisition and convertible financing boost 2026 guidance to $9.00–$9.50 per share.

Via The Motley Fool

Topics Earnings

Ligand Pharmaceuticals (NASDAQ:LGND) Beats Q2 EPS Estimates, Shares Flat on In-Line Revenue ↗

August 06, 2026

Via Chartmill

Ligand Pharmaceuticals Q2 Earnings Call Highlights ↗

August 06, 2026

Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty...

Via MarketBeat

Topics Earnings

$100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

August 05, 2026

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 14.91% on an annualized basis producing an average annual return of 28.27%. Currently, Ligand Pharmaceuticals...

Via Benzinga

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

July 14, 2026

From Ligand Pharmaceuticals

Via GlobeNewswire

XOMA Royalty Announces Closing of Its Acquisition by Ligand

July 14, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Fall on Q1 Revenue and EPS Miss ↗

May 07, 2026

Via Chartmill

Ligand Pharmaceuticals (NASDAQ:LGND) Passes Minervini Trend Template and Growth Screen ↗

April 01, 2026

Via Chartmill

3 Overlooked Stocks Positioned for the Next Market Rotation ↗

July 13, 2026

Oxford Club strategist Marc Lichtenfeld highlights diversification beyond tech, spotlighting Ligand Pharmaceuticals, Aflac and Atlantic Union Bankshares as healthcare, insurance and banking stocks...

Via MarketBeat

Topics Artificial Intelligence

Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned? ↗

June 14, 2026

This biotech innovator, known for its royalty-driven model, reported a notable insider sale amid a period of strong share price gains.

Via The Motley Fool

Topics Regulatory Compliance

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million ↗

June 07, 2026

Biotech royalty player Ligand Pharmaceuticals reported a notable insider sale following a year of strong stock performance.

Via The Motley Fool

Topics Regulatory Compliance

Wealth Manager Sells $7 Million of Establishment Labs After Massive Gains. Is This Medical Device Stock a Buy? ↗

May 30, 2026

Establishment Labs develops advanced silicone implants and medical devices for global plastic surgery markets.

Via The Motley Fool

Topics Regulatory Compliance

OneSpaWorld Posted Record Revenue for Last Quarter. Why Did a Fund Exit a $21.5 Million Stake? ↗

May 29, 2026

OneSpaWorld provides spa, fitness, and beauty services to cruise and resort guests through exclusive wellness partnerships worldwide.

Via The Motley Fool

Topics Regulatory Compliance

Is Genpact Stock a Buy After Hedge Fund Rice Hall James Raised Its Stake by $14 Million? ↗

May 19, 2026

Genpact delivers business process and IT services to global enterprises, with a diversified client base across multiple industries.

Via The Motley Fool

Topics Artificial Intelligence Economy

Is WaterBridge Stock a Buy After Ranger Investment Raised Its Stake by 345,000 Shares? ↗

May 16, 2026

WaterBridge Infrastructure delivers water management and recycling services to oil and gas producers across major U.S. shale basins.

Via The Motley Fool

Topics Initial Public Offering

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

May 12, 2026

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Ligand (LGND) Q1 2026 Earnings Call Transcript ↗

May 12, 2026

Ligand (LGND) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Ligand Pharmaceuticals Q1 Earnings Call Highlights ↗

May 08, 2026

Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from...

Via MarketBeat

Topics Earnings

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

May 06, 2026

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)

May 05, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing ↗

May 04, 2026

Euronet Worldwide encompasses ATM and electronic funds transfer (EFT) services, prepaid distribution, and money transfer, resulting in a more complex structure than that of a typical payments network....

Via The Motley Fool

Topics Regulatory Compliance

Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 Million ↗

May 02, 2026

Specializing in offshore marine support, Tidewater serves global energy clients across oil, gas, and windfarm projects.

Via The Motley Fool

Topics Energy Regulatory Compliance

April 27, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

April 27, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

CLO Sells LGND 5,000 Shares for $1.0 Million ↗

March 30, 2026

Ligand Pharmaceuticals, a leader in drug licensing and royalties, reported a notable insider sale amid strong recent share performance.

Via The Motley Fool

Topics Regulatory Compliance

Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know ↗

March 27, 2026

This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.